Account Info
Log Out
English
Back
Log in to access Online Inquiry
Back to the Top

Buy DXCM to the moon

heres the case for DXCM $DexCom (DXCM.US)$
Stock fell in June due to missed earnings, but likely competitors took opportunity to chum the press. Fundamentally Dexcom is a phenomenal company with the edge on the market as their products have patented tech (most accurate on the market). They have major contracts with large insulin pump providers and cell carriers. They have a follow app for family members to track their loved one’s glucose (think children with diabetes). It’s a critical need in a growing space. Vanguard and Blackrock upped their positions in DXCM. Quant rating 7.77 for quality; 7.66 for growth. Tremendous potental, preferred by physicians, best tech and reach. Excellent R&D with new OTC products. Recently price crossed moving avg (21 day). High Volume. Released Silo product today. Among diabetic community, Dexcom is most trusted. Its a no brainer, fire sale. Expecting 30% upside by Dec 2024.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only. Read more
3
1
+0
3
Translate
Report
86K Views
Comment
Sign in to post a comment
Trader. 6 years of successful experience.
2Followers
5Following
14Visitors
Follow